Cumberland Pharmaceuticals (NASDAQ:CPIX) Announces Quarterly Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, FiscalAI reports. Cumberland Pharmaceuticals had a negative net margin of 6.37% and a positive return on equity of 4.92%. The company had revenue of $13.68 million for the quarter.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Fourth-quarter revenue was $13.7M (+31% YoY) and full-year revenue was $44.5M (+18%), with adjusted earnings of $1.7M ($0.11/share) and operating cash flow of ~$4.9M, reflecting a commercial turnaround and double-digit growth for 2025.
• Ifetroban delivered breakthrough Phase II FIGHT DMD results (high-dose improved LVEF vs placebo and natural-history controls) and has Orphan, Rare Pediatric and Fast Track FDA designations as Cumberland pursues registration for DMD-associated cardiomyopathy.
• Cumberland expanded international reach with Vibativ approval in China, a launch in Saudi Arabia and regulatory approval for its ibuprofen injection in Mexico, plus a $3M China milestone payment supporting global growth.
• The company added Talicia via a joint venture with RedHill (Talicia Holdings, Inc.), began U.S. co-commercialization and now supports its brands with a 50-person national sales and medical organization, broadening its US commercial footprint.
• Despite progress, Cumberland posted a $2.9M full-year net loss and rising operating expenses ($47.3M); acquired brands added large purchase prices but year-end estimated values (~$10M each) and total cash of $11.4M highlight potential asset-valuation and liquidity risks.

Cumberland Pharmaceuticals Stock Performance

Cumberland Pharmaceuticals stock opened at $3.70 on Thursday. Cumberland Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $6.89. The stock’s 50 day simple moving average is $4.17 and its two-hundred day simple moving average is $3.43. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. The stock has a market cap of $55.35 million, a price-to-earnings ratio of -19.47 and a beta of -0.58.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CPIX. Wall Street Zen raised shares of Cumberland Pharmaceuticals to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cumberland Pharmaceuticals presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Heron Bay Capital Management bought a new position in shares of Cumberland Pharmaceuticals in the second quarter worth about $111,000. XTX Topco Ltd bought a new position in shares of Cumberland Pharmaceuticals in the second quarter worth approximately $34,000. Bridgeway Capital Management LLC raised its position in shares of Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the period. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.